咨询与建议

限定检索结果

文献类型

  • 251 篇 期刊文献
  • 4 篇 会议

馆藏范围

  • 255 篇 电子文献
  • 0 种 纸本馆藏

日期分布

学科分类号

  • 108 篇 医学
    • 82 篇 临床医学
    • 57 篇 基础医学(可授医学...
    • 19 篇 药学(可授医学、理...
    • 8 篇 公共卫生与预防医...
  • 100 篇 理学
    • 62 篇 生物学
    • 12 篇 数学
    • 9 篇 物理学
    • 6 篇 化学
    • 5 篇 统计学(可授理学、...
    • 2 篇 天文学
  • 89 篇 工学
    • 36 篇 生物医学工程(可授...
    • 34 篇 计算机科学与技术...
    • 34 篇 软件工程
    • 29 篇 生物工程
    • 9 篇 光学工程
    • 6 篇 信息与通信工程
    • 4 篇 电气工程
    • 4 篇 电子科学与技术(可...
    • 3 篇 控制科学与工程
    • 3 篇 化学工程与技术
    • 2 篇 力学(可授工学、理...
    • 2 篇 材料科学与工程(可...
    • 2 篇 建筑学
    • 2 篇 土木工程
    • 2 篇 安全科学与工程
  • 27 篇 农学
    • 7 篇 作物学
  • 19 篇 管理学
    • 10 篇 管理科学与工程(可...
    • 5 篇 图书情报与档案管...
    • 4 篇 工商管理
    • 4 篇 公共管理
  • 2 篇 教育学
  • 1 篇 哲学

主题

  • 7 篇 pathology
  • 4 篇 cancer
  • 4 篇 diseases
  • 4 篇 tumors
  • 3 篇 computational bi...
  • 3 篇 machine learning
  • 3 篇 gene expression
  • 2 篇 human papillomav...
  • 2 篇 deep learning
  • 2 篇 generative adver...
  • 2 篇 image segmentati...
  • 2 篇 predictive marke...
  • 2 篇 risk factors
  • 2 篇 cancer immunothe...
  • 2 篇 stage at diagnos...
  • 2 篇 genome-wide asso...
  • 2 篇 mortality
  • 2 篇 breast cancer
  • 2 篇 cervical cancer
  • 2 篇 epigenetic regul...

机构

  • 12 篇 cancer program b...
  • 11 篇 department of da...
  • 10 篇 department of in...
  • 10 篇 department of bi...
  • 9 篇 department of bi...
  • 9 篇 department of me...
  • 9 篇 dana-farber canc...
  • 8 篇 department of pa...
  • 7 篇 institute for ca...
  • 7 篇 department of mo...
  • 7 篇 department of tw...
  • 7 篇 department of pa...
  • 7 篇 department of me...
  • 7 篇 cancer data scie...
  • 7 篇 department of pa...
  • 7 篇 harvard medical ...
  • 7 篇 broad institute ...
  • 7 篇 data science pro...
  • 6 篇 national institu...
  • 6 篇 cancer program b...

作者

  • 26 篇 mahmood faisal
  • 20 篇 williamson drew ...
  • 19 篇 lu ming y.
  • 15 篇 chen tiffany y.
  • 14 篇 chen richard j.
  • 9 篇 jaume guillaume
  • 9 篇 lipkova jana
  • 8 篇 wei zheng
  • 7 篇 caroline hayward
  • 7 篇 song andrew h.
  • 6 篇 timothy m frayli...
  • 6 篇 danish saleheen
  • 6 篇 eleftheria zeggi...
  • 6 篇 mark i mccarthy
  • 6 篇 kari stefansson
  • 6 篇 macarthur daniel...
  • 6 篇 ezhov ivan
  • 6 篇 kofler florian
  • 6 篇 chen bowen
  • 6 篇 menze bjoern

语言

  • 248 篇 英文
  • 5 篇 其他
  • 2 篇 中文
检索条件"机构=Cancer Data Science Program"
255 条 记 录,以下是51-60 订阅
排序:
Tumor Immunophenotypic Correlates in Patients Aged 80 Years or Older With Non-Small Cell Lung cancer and Outcomes to First-Line Pembrolizumab in PD-L1 High (≥50%) Patients
收藏 引用
Clinical Lung cancer 2025年 第4期26卷 288-298.e8页
作者: Barrichello, Adriana P.C. Elkrief, Arielle Ricciuti, Biagio Ganta, Teja Marron, Thomas U. Wang, Xinan Lotter, William Lindsay, James Santo, Valentina Cortellini, Alessio Sharma, Bijaya Felt, Kristen Pfaff, Kathleen Lamberti, Giuseppe Pecci, Federica Federico, Alessandro Di Makarem, Maisam Gandhi, Malini M. Nguyen, Tom Haradon, Danielle Vaz, Victor R. Johnson, Bruce E. Debnath, Neha Wang, Yinghong Kuang, Andrew G. Saeed, Anwaar Radford, Maluki Lovly, Christine M. Nebhan, Caroline A. Pinato, David J. Rodig, Scott J. Schoenfeld, Adam J. Awad, Mark M. Alessi, Joao V. Naqash, Abdul Rafeh Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Boston MA United States Thoracic Oncology Center Memorial Sloan Kettering Cancer Center New York NY United States Tisch Cancer Institute Icahn School of Medicine at Mount Sinai New York NY United States Department of Environmental Health Harvard T.H. Chan School of Public Health Harvard University Boston MA United States Department of Data Science Dana-Farber Cancer Institute Boston MA United States Department of Surgery and Cancer Imperial College London Faculty of Medicine Hammersmith Hospital London United Kingdom ImmunoProfile Brigham and Women's Hospital and Dana-Farber Cancer Institute Boston MA United States Center for Immuno-oncology Dana-Farber Cancer Institute Boston MA United States Department of Gastroenterology Hepatology & Nutrition University of Texas MD Anderson Cancer Center Houston TX United States Department of Internal Medicine Baylor College of Medicine Houston TX United States Division of Medical Oncology Department of Medicine Kansas University Medical Center Westwood KS United States Department of Medicine and Vanderbilt-Ingram Cancer Center Vanderbilt University Nashville TN United States Department of Pathology Brigham and Women's Hospital Boston MA United States Medical Oncology/TSET Phase 1 Program Stephenson Cancer Center University of Oklahoma Oklahoma City OK United States
Background: Non-small cell lung cancer (NSCLC) patients aged ≥80 years [y] are underrepresented in clinical trials. We evaluated whether age correlates with a distinct immunophenotype or impacts outcomes to first-lin... 详细信息
来源: 评论
Precision Rehabilitation for Patients Post-Stroke based on Electronic Health Records and Machine Learning
arXiv
收藏 引用
arXiv 2024年
作者: Gao, Fengyi Zhang, Xingyu Sivarajkumar, Sonish Denny, Parker E. Aldhahwani, Bayan M. Visweswaran, Shyam Shi, Ryan Hogan, William Bove, Allyn Wang, Yanshan Department of Health Information Management University of Pittsburgh PittsburghPA United States Department of Communication Science and Disorders University of Pittsburgh PittsburghPA United States Intelligent Systems Program School of Computing and Information University of Pittsburgh PittsburghPA United States Department of Physical Therapy University of Pittsburgh PittsburghPA United States Department of Medical Rehabilitation Sciences Umm Al-Qura University Makkah Saudi Arabia Department of Biomedical Informatics University of Pittsburgh PittsburghPA United States Department of Computer Science University of Pittsburgh Medical Center PittsburghPA United States Data Science Institute Medical College of Wisconsin MilwaukeeWI United States Hillman Cancer Center University of Pittsburgh Medical Center PittsburghPA United States
Objective In this study, we utilized statistical analysis and machine learning methods to examine whether rehabilitation exercises can improve patients post-stroke functional abilities, as well as forecast the improve... 详细信息
来源: 评论
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
收藏 引用
Nature Communications 2025年 第1期16卷 1-13页
作者: Barroso-Sousa, Romualdo Zanudo, Jorge Gomez Tejeda Li, Tianyu Reddy, Sangeetha M. Emens, Leisha A. Kuntz, Thomas M. Silva, Carolina Alves Costa AlDubayan, Saud H. Chu, Hoyin Overmoyer, Beth Lange, Paulina DiLullo, Molly K. Montesion, Meagan Kasparian, Julie Hughes, Melissa E. Attaya, Victoria Basta, Ameer Lin, Nancy U. Tayob, Nabihah Jeselsohn, Rinath Mittendorf, Elizabeth A. Tolaney, Sara M. Hospital Brasília Rede Américas Brasilia Brazil Medical Oncology Dana-Farber Cancer Institute Boston MA United States Breast Oncology Program Dana-Farber Brigham Cancer Center Boston MA United States Harvard Medical School Boston MA United States Data Science Dana-Farber Cancer Institute Boston MA United States University of Texas Southwestern Medical Center Dallas TX United States University of Pittsburgh Medical Center Pittsburgh PA United States Department of Biostatistics Harvard T. H. Chan School of Public Health Boston MA United States Gustave Roussy Cancer Campus (GRCC) Clinicobiome Cedex Villejuif France Foundation Medicine Inc. Boston MA United States Division of Breast Surgery Department of Surgery Brigham and Women’s Hospital Boston MA United States
In the phase II NIMBUS trial, patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) and high tumor mutational burden (TMB ≥ 9 mut/Mb) received nivolumab (3 mg/kg biweek...
来源: 评论
Projected Time for the Elimination of Cervical cancer Under Various Intervention Scenarios: Age-Period-Cohort Macrosimulation Study
收藏 引用
JMIR Public Health and Surveillance 2024年 10卷 e46360页
作者: Chen, Yi-Chu Chen, Yun-Yuan Su, Shih-Yung Jhuang, Jing-Rong Chiang, Chun-Ju Yang, Ya-Wen Lin, Li-Ju Wu, Chao-Chun Lee, Wen-Chung Institute of Epidemiology and Preventive Medicine College of Public Health National Taiwan University Taipei Taiwan Head Office Taiwan Blood Services Foundation Taipei Taiwan Master Program in Statistics National Taiwan University Taipei Taiwan Institute of Statistical Science Academia Sinica Taipei Taiwan Taiwan Cancer Registry Taipei city Taiwan Health Promotion Administration Ministry of Health and Welfare Taipei Taiwan Institute of Health Data Analytics College of Public Health National Taiwan University Taipei Taiwan
BACKGROUND: The World Health Organization aims for the global elimination of cervical cancer, necessitating modeling studies to forecast long-term outcomes. OBJECTIVE: This paper introduces a macrosimulation framework... 详细信息
来源: 评论
Managing the transition in cervical screening methods for Taiwan: Policy recommendations and perspectives
收藏 引用
Journal of the Formosan Medical Association 2023年 第11期122卷 1213-1218页
作者: Chen, Chien-Chin Lai, Chyong-Huey Chang, Chih-Long Cheng, Wen-Fang Pwu, Raoh-Fang Tsai, Jane Wang, Peng-Hui Whang-Peng, Jacqueline Lai, Gi-Ming Department of Pathology Ditmanson Medical Foundation Chia-Yi Christian Hospital Chiayi 600 Taiwan Department of Cosmetic Science Chia Nan University of Pharmacy and Science Tainan 717 Taiwan Ph.D. Program in Translational Medicine Rong Hsing Research Center for Translational Medicine National Chung Hsing University Taichung 402 Taiwan Department of Biotechnology and Bioindustry Sciences College of Bioscience and Biotechnology National Cheng Kung University Tainan 701 Taiwan Department of Obstetrics and Gynecology Chang Gung Memorial Hospital Linkou Branch Taoyuan 333 Taiwan Chang Gung University Taoyuan 333 Taiwan Department of Medicine MacKay Medical College New Taipei City 252 Taiwan Department of Obstetrics and Gynecology MacKay Memorial Hospital Taipei 104 Taiwan Department of Obstetrics and Gynecology College of Medicine National Taiwan University Taipei 100 Taiwan School of Health Care Administration Taipei Medical University Taipei 110 Taiwan Data Science Center Fu Jen Catholic University New Taipei City 242 Taiwan Formosa Cancer Foundation Taipei 105 Taiwan Department of Obstetrics and Gynecology Taipei Veterans General Hospital Taipei 112 Taiwan National Yang Ming Chiao Tung University Taipei 112 Taiwan
Since government-provided annual cervical cytology testing for all Taiwanese women aged 30 years or older became available in 1995, both cervical cancer incidence and death have decreased significantly. However, with ... 详细信息
来源: 评论
Expression of HLA-B35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation
收藏 引用
Transplantation and Cellular Therapy 2025年 第2期31卷 S519-S519页
作者: Little, Jessica S., MD Hebert, Kyle, MS Neuberg, Donna, ScD Nikiforow, Sarah, MD, PhD Gooptu, Mahasweta, MD Shapiro, Roman M., MD Koreth, John, MBBS, DPhil Antin, Joseph H., MD Cutler, Corey S., MD MPH Soiffer, Robert J., MD Ritz, Jerome, MD Romee, Rizwan, MD Ho, Dr. Vincent T., MD Issa, Nicolas, M.D. Baden, Lindsey, MD Dulery, Remy, MD, PhD Prockop, Susan E., MD Division of Stem Cell Transplantation and Cellular Therapy Dana-Farber Cancer Institute and Harvard Medical School Boston MA Division of Infectious Diseases Brigham and Women's Hospital Boston MA Department of Data Science Dana-Farber Cancer Institute Boston MA Department of Data Science Dana Farber Cancer Institute Boston MA Department of Medical Oncology Dana-Farber Cancer Institute Boston MA Department of Medical Oncology Dana-Farber Cancer Institute and Harvard Medical School Boston MA Dana-Farber Cancer Institute Boston MA Division of Stem Cell Transplant and Cellular Therapy Dana-Farber Cancer Institute and Harvard Medical School Boston MA Hematopoietic Stem Cell Transplant Program Dana Farber Cancer Institute Boston Children's Hospital and Harvard Medical School Boston MA
IntroductionHematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GvHD) prophylaxis carries a higher risk of cytomegalovirus (CMV) infections despite letermovi...
来源: 评论
Targeting the intracellular immune checkpoint CISH with CRISPR-Cas9-edited T cells in patients with metastatic colorectal cancer: a first-in-human, single-centre, phase 1 trial
收藏 引用
The Lancet Oncology 2025年 第5期26卷 559-570页
作者: Lou, Emil Choudhry, Modassir S Starr, Timothy K Folsom, Timothy D Bell, Jason Rathmann, Blaine DeFeo, Anthony P Kim, Jihyun Slipek, Nicholas Jin, Zhaohui Sumstad, Darin Klebanoff, Christopher A Ladner, Katherine Sarkari, Akshat McIvor, R Scott Murray, Thomas A Miller, Jeffrey S Rao, Madhuri Jensen, Eric Ankeny, Jacob Khalifa, Mahmoud A Chauhan, Anil Spilseth, Benjamin Dixit, Ajay Provenzano, Paolo P Pan, Wenjing Weber, Daniel Byrne-Steele, Miranda Henley, Tom McKenna, David H Johnson, Matthew J Webber, Beau R Moriarity, Branden S Department of Medicine Division of Hematology Oncology and Transplantation University of Minnesota Minneapolis MN United States Department of Obstetrics Gynecology and Women's Health University of Minnesota Minneapolis MN United States Department of Pediatrics University of Minnesota Minneapolis MN United States Masonic Cancer Center University of Minnesota Minneapolis MN United States Center for Genome Engineering University of Minnesota Minneapolis MN United States Department of Genetics Cell Biology and Development University of Minnesota Minneapolis MN United States Department of Biomedical Engineering University of Minnesota Minneapolis MN United States Center for Multiparametric Imaging of Tumor Immune Microenvironments University of Minnesota Minneapolis MN United States Stem Cell Institute University of Minnesota Minneapolis MN United States Intima Bioscience New York NY United States Deparment of Medical Oncology Mayo Clinic Rochester MN United States Cell Therapy Clinical Laboratory University of Minnesota Medical School Minneapolis MN United States Division of Biostatistics and Health Data Science University of Minnesota Medical School Minneapolis MN United States Department of Surgery University of Minnesota Medical School Minneapolis MN United States Department of Laboratory Medicine and Pathology University of Minnesota Medical School Minneapolis MN United States Department of Radiology University of Minnesota Medical School Minneapolis MN United States Department of Medicine Human Oncology and Pathogenesis Program and Parker Institute for Cancer Immunotherapy Memorial Sloan Kettering Cancer Center New York NY United States Department of Radiology University of Kansas Medical Center Kansas City KS United States Division of Gastroenterology Hepatology and Nutrition Cincinnati Children's Hospital Medical Center Cincinnati OH United States iRepertoire Huntsville AL United States
Background: Over the past decade, immunotherapeutic strategies—mainly targeting the PD-1–PD-L1 immune checkpoint axis—have altered cancer treatment for many solid tumours, but few patients with gastrointestinal for...
来源: 评论
Correction to: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy (Nature Biotechnology, (2025), 10.1038/s41587-024-02535-2)
收藏 引用
Nature Biotechnology 2025年
作者: Zhang, Feifei Chow, Ryan D. He, Emily Dong, Chuanpeng Xin, Shan Mirza, Daniyal Feng, Yanzhi Tian, Xiaolong Verma, Nipun Majety, Medha Zhang, Yueqi Wang, Guangchuan Chen, Sidi Department of Genetics Yale University School of Medicine New HavenCT United States System Biology Institute Yale University West HavenCT United States Center for Cancer Systems Biology Yale University West HavenCT United States M.D.–Ph.D. Program Yale University West HavenCT United States Molecular Cell Biology Genetics and Development Program Yale University New HavenCT United States Yale College New HavenCT United States Immunobiology Program Yale University New HavenCT United States Department of Therapeutic Radiology Yale University School of Medicine New HavenCT United States Department of Neurosurgery Yale University School of Medicine New HavenCT United States Yale Comprehensive Cancer Center Yale University School of Medicine New HavenCT United States Yale Stem Cell Center Yale University School of Medicine New HavenCT United States Yale Center for Biomedical Data Science Yale University School of Medicine New HavenCT United States Key Laboratory of Multi-Cell Systems Shanghai Institute of Biochemistry and Cell Biology Center for Excellence in Molecular Cell Science Chinese Academy of Sciences Shanghai China
Correction to: Nature Biotechnologyhttps://***/10.1038/s41587-024-02535-2, published online 16 January 2025. In the version of the article initially published, Sidi Chen was incorrectly associated with a present addre...
来源: 评论
Outcomes of Patients with Hematologic Malignancies and COVID-19 Infection: A Report from the ASH Research Collaborative data Hub
收藏 引用
BLOOD 2020年 136卷 7-8页
作者: Wood, William A. Neuberg, Donna S. Thompson, John Colton Tallman, Martin S. Sekeres, Mikkael A. Sehn, Laurie H. Anderson, Kenneth Goldberg, Aaron D. Pennell, Nathan A. Niemeyer, Charlotte M. Tucker, Emily Hewitt, Kathleen Plovnick, Robert M. Hicks, Lisa K. Division of Hematology Department of Medicine University of North Carolina Chapel Hill NC Department of Data Science Dana-Farber Cancer Institute Boston MA ASH Research Collaborative Washington DC Memorial Sloan-Kettering Cancer Center New York NY Leukemia Program Department of Hematology and Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH British Columbia Cancer Agency Vancouver Canada Jerome Lipper Multiple Myeloma Center LeBow Institute for Myeloma Therapeutics Dana-Farber Cancer Institute Harvard Medical School Boston MA Department of Medicine Leukemia Service Memorial Sloan-Kettering Cancer Center New York NY Lung Program Medical Oncology Cleveland Clinic Taussig Cancer Institute Cleveland OH University Children's Hospital Freiburg Germany ASH Research Collaborative Washington DC DC American Society of Hematology Washington DC DC Division of Hematology/Oncology St. Michael's Hospital Toronto Canada
Introduction: The coronavirus disease 2019 (COVID-19) is an illness resulting from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that emerged in late 2019. Many patients with blood cancer have underlyin...
来源: 评论
Phase I Study of Ixazomib with Conventional Chemotherapy in the Treatment of Acute Myeloid Leukemia in Older Adults
收藏 引用
BLOOD 2020年 136卷 7-8页
作者: Amrein, Philip C. Attar, Eyal C. Fell, Geoffrey Blonquist, Traci M. Brunner, Andrew M. Hobbs, Gabriela S. Hock, Hanno R. McAfee, Steven L. Narayan, Rupa Moran, Jenna A. Bergeron, Meghan Foster, Julia E. Bertoli, Christina McGregor, Kristin Macrae, Molly Burke, Meghan Behnan, Tanya T. Som, Tina T. Ramos, Aura Y. Vartanian, Megan K. Story, Jennifer Lombardi Neuberg, Donna S. Fathi, Amir T. Leukemia Center/MGH Cancer Center Massachusetts General Hospital Belmont MA Agios Boston MA Data Science Dana-Farber Cancer Institute Boston MA Center for Leukemia Massachusetts General Hospital Boston MA Leukemia Center Massachusetts General Hospital Boston MA Leukemia Center Massachusetts General Hospital / Harvard Medical School Boston MA Massachusetts General Hospital Blood and Marrow Transplant Program Boston MA Leukemia Center Massachusetts General Hospital Center for Leukemia Cambridge MA
Introduction: Outcomes for acute myeloid leukemia (AML) among older patients has remained largely unchanged for decades. Long-term survival for patients aged >60 years is poor (median survival 10.5 months). Targeti...
来源: 评论